Correlation of tumor mutation with efficacy in patients with gastric cancer who received nivolumab and ramucirumab combination therapy.

Izuma Nakayama,Hirokazu Shoji,Hiroki Hara,Taito Esaki,Nozomu Machida,Kengo Nagashima,Kazunori Aoki,Kazufumi Honda,Daisuke Takahari,Takahiro Miyamoto,Narikazu Boku,Ken Kato

Correlation of tumor mutation with efficacy in patients with gastric cancer who received nivolumab and ramucirumab combination therapy.

2020

Izuma Nakayama
Hirokazu Shoji
Hiroki Hara
Taito Esaki
Nozomu Machida
Kengo Nagashima
Kazunori Aoki
Kazufumi Honda
Daisuke Takahari
Takahiro Miyamoto
Narikazu Boku
Ken Kato

413Background: Nivolumab (Nivo) plus ramucirumab (Ram) showed promising efficacy in the second-line chemotherapy for advanced gastric cancer (AGC) in NIVORAM study with the 44% of objective respons...

Keywords:

Cancer
Internal medicine
Mutation
Combination therapy
Nivolumab
Medicine
Oncology
Pathology
Ramucirumab
in patient
advanced gastric cancer
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations